Effect of glutamine on the mRNA level of key enzymes of malate-aspartate shuttle in the rat intestine subjected to ischemia reperfusion

Efeito da glutamina sobre o nível de RNA Mensageiro das enzimas-chave do ciclo malato-aspartato no intestino de ratos submetidos à isquemia e reperfusão

ABSTRACT

PURPOSE: To determine the effects of oral L-glutamine (L-Gln) and the dipeptide l-alanyl-glutamine (L-Ala-Gln) upon the activity of the malate-aspartate shuttle in the rat distal small intestine following ischemia and reperfusion.

METHODS: Seventy-two Wistar rats (350-400g), were randomized in 2 groups (n = 36): group S (Sham) and Group T (Treatment) and divided into 12 subgroups (n = 6): A-A6, and B1-B6. The subgroups A1-A3 were subjected to sham procedures at 30 and 60 minutes. Thirty minutes before the study, rats were treated with calcium caseinate, 0.5g/Kg (subgroups A1, A4, B1, B4), L-Gln, 0.5g / kg (subgroups A2, A5, B2 and B5) or L-Ala-Gln, 0.75g/Kg (subgroups A3, A6, B3, B6), administered by gavage. Ischemia was achieved by clamping the mesenteric vessels, delimiting a segment of bowel 5 cm long and 5 cm apart from the ileocecal valve. Samples were collected 30 and 60 minutes after start of the study for real-time PCR assay of malate dehydrogenases (MDH1-2) and aspartate-aminotransferases (GOT1-2) enzymes.

RESULTS: Tissue MDH and GOT mRNA expression in intestinal samples from rats preconditioned with either L-Gln or L-Ala-Gln showed no significant differences both during ischemia and early reperfusion.

CONCLUSION: Activation of the malate-aspartate shuttle system appears not to be the mechanism of glutamine-mediated elevation of glucose oxidation in rat intestine during ischemia/reperfusion injury.

Effect of glutamine on the mRNA level of key enzymes of malate-aspartate shuttle in the rat intestine subjected to ischemia reperfusion

Introduction

Small bowel ischemia/reperfusion (IR) injury is a well known condition. Ischemia progressively damages the cell structures and, following the restoration of blood flow, lesions produced are further exacerbated.\(^2\)

L-Glutamine (L-Gln), a five-carbon amino acid, formerly classified as a non-essential, is the most abundant amino acid in blood and tissue fluids and is considered to be essential during certain catabolic conditions.\(^3\) Some studies have shown that L-Gln reduces atrophy of intestinal mucosa in animals subjected to total parenteral nutrition and prevents intestinal mucosal injury accompanying small bowel transplantation, chemotheraphy and radiation.\(^4\) Studies established that L-Gln is the main respiratory fuel of enterocytes. It was demonstrated that carbon derived from L-Gln contributed 46% of the carbon dioxide released from isolated perfused segments of rat jejunum.\(^5\) In addition to its role as a fuel, L-Gln may be important to the small intestine because it is also a source of substrates for the synthesis of nucleic acids. Indeed, it has been argued that one reason for the high rate of L-Gln degradation in enterocytes and other cells, such as lymphocytes and macrophages, is to ensure regulation of the rate of nucleic acid synthesis.\(^6\)

Experimental studies have demonstrated pro-glycolytic effect of L-Gln or dipeptide L-Alanyl-glutamine (L-Ala-Gln) when offered in nutraceutical doses.\(^7\) L-Ala-Gln is a highly stable dipeptide and when infused intravenously is promptly hydrolyzed to L-Gln and alanine.\(^8\)

The malate-aspartate shuttle is a biochemical system for translocating electrons produced during glycolysis across the impermeable inner membrane of the mitochondria for oxidative phosphorylation in eukaryotes. It is not known whether L-Gln supplementation may induce changes in the level or distribution of mRNA of enzymes of malate aspartate shuttle. Therefore the aim of this study was to examine the effects of L-Gln and L-Ala-Gln oral supplementation, on intestinal ischemia-reperfusion injury on the intestinal mucosa levels of the RNA Messenger (mRNA) of the key enzymes involved in the malate-aspartate shuttle, i.e., Malate dehydrogenases (malate dehydrogenase 1, NAD, soluble - MDH1 and malate dehydrogenase 2, NAD, mitochondrial - MDH2) and Aspartate-aminotransferases (glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1 - GOT1 and glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2 - GOT2).

Methods

Approval (Protocol #06/07) for experimental use of laboratory animals was obtained from the Ethics Committee on Animal Research (CEPA) of the Federal University of Ceara, now Ethics Committee on the Use of Animals (CEUA), in view of the Federal Law No. 11794 of October 8, 2008, http://www.planalto.gov.br/ccivil_03/_Ato2007-2010/2008/Lei/L11794.htm and Decree No. 6689 of July 15, 2009 that regulated the Law 11794, available at: http://www.planalto.gov.br/ccivil_03/_Ato2007-2010/2009/Decreto/D6899.htm. The study was designed so as to minimize the number of animals required for the experiments.

Seventy-two healthy Wistar rats (350-400g) were randomized in 2 groups (n = 36): group S (Sham) and Group T (Treatment). The rats in each group were distributed in 12 subgroups (n = 6): A-A6, and B1-B6. The subgroups A1-A3 were subjected to sham procedures (laparotomy and handling of the bowel, without clamping or ischemia). This procedure was repeated at 30 and 60 minutes. Thirty minutes before the start of the study, rats were treated with calcium caseinate, 0.5 g/Kg (subgroups A1, A4, B1, B4), L-Gln, 0.5g / kg (subgroups A2, A5, B2 and B5) or L-Ala-Gln, 0.75g/Kg (subgroups A3, A6, B3, B6), administered by gavage.

Induction of ischemia and samples harvesting

Before the induction of anesthesia, each rat was fasted for 12 h before IR injury but was allowed free access to water. The rats were anesthetized by an intra-peritoneal injection of xylazine (10 mg/kg) and ketamine (60 mg/kg). Ischemia was induced as described by Lindestrom et al.\(^10\). In brief, using sterile techniques, the abdomen was opened using a midline incision. After laparotomy, a segment of ileum 5 cm apart from the ileocecal valve was isolated. Ischemia was achieved by clamping the mesenteric vessels using three micro-clamps normally used for neurosurgery, delimiting a segment of bowel 5 cm long (Figure 1). During the period of ischemia the abdominal wall incision was closed with nylon 4-0 stitches to prevent fluid and heat loss. After 30 minutes (ischemic cycle) the abdominal cavity was reopened with the removal of stitches (Figure 2). In ischemia group the ischemic bowel segment was removed, blotted dry, weighed, and slit down the antimesenteric border for mucosal removal. The sample of intestinal mucosa was weighed and stored for the estimation of enzymes activity and mRNA concentration. In ischemia-reperfusion group the clamps were removed allowing the restoration of blood flow. Before closure of the abdominal cavity, the reperfusion was confirmed by the reappearance of pulsation in the mesentery arcade and the change in color of the loops of the small bowel. After another 30 minutes, the cavity was reopened and the ischemic segment was removed and treated as described above. Rats of Sham group (subgroups A1-A3) were subjected to laparotomy and handling of the bowel, without clamping or ischemia for 30 minutes. This procedure was repeated 30 minutes later for sample collection. The abdominal cavity was closed and reopened 30 minutes later for sample collection (subgroups A4-A6). Once completed all experimental procedures, all animals were killed by an overdose of anesthetics.
**Primers Forward Reverse**

**GOT1** - NM_012571  
TGCCTGGGCTATTCGCTATTTAATCCGGTCAGCCATTGTCTT

**GOT2** – NM_013177  
ATCGAGCAGGGCATCAATGTAAGGCCCATGTTCTTGGCATA

**MDH1** - NM_033235  
GGGAAATCATTCATCAACCCCTTCCTTGCAATTTCACCTTGG

**MDH2** - NM_031151  
TTGCATCATTTCCAACCCAGTGAAAACTTCGGCTGTGATGG

---

**Real-time PCR**

Quantitative real-time PCR (qPCR) was performed using the SyBr Green PCR® master mix (Invitrogen Brasil Ltda, Sao Paulo, Brazil) in 96-well plates with 5µL volume per well and each sample analyzed in duplicate. The amplifications were performed on an ABI PRISM 7500 Sequence Detection System® and software (Applied Biosystems of Brazil, Sao Paulo, Brazil). To control for variability in amplification due to differences in starting RNA concentrations, RPL13A was used as internal standard. The amount of RNA used for the cDNA synthesis was 0.5µg. The primers used for amplification of genes encoding GOT 1 and 2, MDH 1 and 2, RPL13A were designed by Primer Express program (Applied Biosystems, USA) based on sequences deposited in GenBank (http://www.ncbi.nlm.nih.gov). The sequences of primers and size of amplified fragments are listed below (Table 1).

**Statistical analysis**

Graphpad Prism 5.0 (GraphPad Software, San Diego,CA, USA, www.graphpad.com) was used for statistical analysis and graphics design. All data are expressed as mean ± standard deviation. Comparisons were made using one-way ANOVA followed by Bonferroni post test. A p value of < 0.05 was considered statistically significant.

---

**TABLE 1** – Sequence of primers and size of amplified segments (GOT1, GOT2, MDH1, MDH2).

<table>
<thead>
<tr>
<th>Primers</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOT1 - NM_012571</td>
<td>TGCCTGGGCTATTCGCTATTT</td>
<td>AATCCGGTCAGCCATTGTCTT T</td>
</tr>
<tr>
<td>GOT2 – NM_013177</td>
<td>ATCGAGCAGGGCATCAATGT</td>
<td>AAGCCCATGGTTTTTGGCATA</td>
</tr>
<tr>
<td>MDH1 - NM_033235</td>
<td>GGGAAATCATTCATCAACCCA</td>
<td>TTTCTTGCAATTTCACCTTGG</td>
</tr>
<tr>
<td>MDH2 - NM_031151</td>
<td>TGCATCATTTCCACCCAG</td>
<td>TGAAAACCTGGCTGTGATGG</td>
</tr>
</tbody>
</table>

---

**FIGURE 1** – Induction of ischemia. Aspect of the small bowel immediately after placement of vascular microclamps.

**FIGURE 2** – Appearance of the ischemic small bowel segment after 30 minutes of ischemia (microclamps are visible).
Results

No animal died during the experiment. Pretreatment with L-Ala-Gln or L-Gln did not change the mRNA levels of malate-aspartate shuttle key enzymes MDH1 (soluble), MDH2 (non soluble), GOT1 (soluble) and GOT2 (non soluble) in the rat intestine subjected to ischemia and or ischemia/reperfusion (Figures 3 to 10).

**FIGURE 3** – MDH1 – Percentage (%) of mRNA relative to RPL13a, in groups Sham (A1-A3) and Ischemia (B1-B3) (30 minutes). Groups studied are not significantly different by one-way ANOVA followed by Bonferroni post test.

**FIGURE 4** – MDH1 – Percentage (%) of mRNA relative to RPL13a, in groups Sham (A4-A6) and Ischemia/Reperfusion (B4-B6) (60 minutes). Groups studied are not significantly different by one-way ANOVA followed by Bonferroni post test.

**FIGURE 5** – MDH2 – Percentage (%) of mRNA relative to RPL13a, in groups Sham (A1-A3) and Ischemia (B1-B3) (30 minutes). Groups studied are not significantly different by one-way ANOVA followed by Bonferroni post test.

**FIGURE 6** – MDH2 - Percentage (%) of mRNA relative to RPL13a, in groups Sham (A4-A6) and Ischemia/Reperfusion (B4-B6) (60 minutes). Groups studied are not significantly different by one-way ANOVA followed by Bonferroni post test.

**FIGURE 7** – GOT1 – Percentage (%) of mRNA relative to RPL13a, in groups Sham (A1-A3) and Ischemia (B1-B3) (30 minutes). Groups studied are not significantly different by one-way ANOVA followed by Bonferroni post test.
Discussion

Published studies showed that administration of L-Gln or L-Ala-Gln in various pathological conditions may enhance both anaerobic11-12 and aerobic glycolysis13. Other researchers have used the infusion of L-Ala-L-Gln associated with parenteral nutrition in Intensive Care Units patients14 and in patients with traumatic injury15. It was demonstrated that both L-Gln as well as L-Ala--Gln peptides have enhanced glucose utilization resulting in decreased glucose blood levels in those patients.

It was hypothesized in this study was that the offer of L-Gln or L-Ala-Gln by gavage, prior to ischemia/reperfusion, would provide greater availability to tissues rich in glutaminase, such as the small intestine promoting enhanced activation of this shuttle, leading to increased activity of the first phase of the glycolytic pathway in these tissues.

Therefore, in order to clarify the role of the malate-aspartate shuttle in the pro-glycolytic action of glutamine, we attempted to evaluate RT-PCR via the messenger RNA of key enzymes of the shuttle (RNA1 and RNA2 of GOT1, GOT2, MDH1 and MDH2). However, as demonstrated in our results, the offer of L-Gln or L- Ala-Gln to rats submitted to I/R did not induce changes in messenger RNA expression of these enzymes (Figures 3 to 10). The absence of similar studies in the medical literature did not allow a comparative analysis of these results. Other cellular mechanisms either via new formed proteins or through glutamate transporters, such as citrin or aralar-1, may elucidate further the glycolytic action of glutamine and its dipeptide l-alanyl-glutamine16-17.

Conclusion

Activation of the malate-aspartate shuttle system appears not to be the mechanism of glutamine-mediated elevation of glucose oxidation in rat intestine during ischemia/reperfusion injury.

References

Effect of glutamine on the mRNA level of key enzymes of malate-aspartate shuttle in the rat intestine subjected to ischemia reperfusion


Correspondence:
Sergio Botelho Guimarães
Rua Professor Costa Mendes, 1608/3º andar, Bloco Didático
60430-140 Fortaleza – CE Brasil
Tel.: (55-85)3366-8083
Fax: (55-85)3366-8064
sergiobotelho@terra.com.br

Conflict of interest: none
Financial source: CNPq

1Research performed at Experimental Surgery Laboratory (LABCEX), Faculty of Medicine, Federal University of Ceara (UFC), Fortaleza and Biochemistry and Cell Biology Laboratory, University of Sao Paulo (USP), Ribeirao Preto, Brazil.